Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
Status:
Completed
Trial end date:
2020-11-09
Target enrollment:
Participant gender:
Summary
This is a phase Ib study with the primary purpose is to estimate the MTD and/or RDE for the
triple combination of PIM447, formerly LGH447, plus ruxolitinib and LEE011 as well as for the
doublets, PIM447 plus ruxolitinib, and LEE011 plus ruxolitinib, in patients with
myelofibrosis (MF). Each regimen will be assessed for safety, tolerability, pharmacokinetics
(PK) and pharmacodynamic effects, and preliminary anti-myelofibrosis activity, including
changes in spleen volume, JAK2V617F allele burden, and hematologic response.